LONDON (Reuters) GlaxoSmithKline leukemia drug Arzerra, licensed from Denmark's Genmab, has been rejected by Britain's cost watchdog NICE in preliminary draft guidance.The National Institute for Health and Clinical Excellence (NICE) said on Thursday it could not recommend the drug for reimbursement on the National Health Service (NHS) because evidence did not yet show how well it compared with s